And these posts are what Ignore was invented for. But anyway....

And these posts are what Ignore was invented for. But anyway. Everyone is jumping at shadows right now. How about we look at the facts?

The cost of executing a pipeline of trials and activities was fully accounted for and the CR was oversubscribed.

Outgoing roles match incoming new hires' salaries.

Companies receive R&D refunds that become contingency cash for donations, travel, additional research opportunities.

RAC are in a great financial position. If more capital is required, I would think we're about ready to be talking to potential suitors about mutually beneficial financial arrangements based on "our exceptional pre-clinical database". The scale of future clinical sites would require investment beyond what Aussie investors are capable of putting in - or based on some of the commentary on here, capable of understanding deeply enough to appreciate value or timelines.